Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms PHOENIX-1
  • Sponsors Centocor

Most Recent Events

  • 09 Feb 2019 1 -year safety data from 12 ustekinumab registrational trials published in the Drug Safety.
  • 08 Mar 2016 Results of pooled analysis assessing the association between HLA-Cw6 status and efficacy of ustekinumab from Phoenix 1, Phoenix 2, and ACCEPT studies, presented at the 74th Annual Meeting of the American Academy of Dermatology.
  • 28 Sep 2012 Safety data from a pooled analysis of this and the PHOENIX-2 and ACCEPT trials were presented at the 21st European Academy of Dermatology and Venereology (EADV) congress in late September 2012.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top